Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Renovis Cuts Workforce By 40 Percent To Focus On Preclinical Compounds

This article was originally published in The Pink Sheet Daily

Executive Summary

Eliminations follow Phase III failure of an acute ischemic stroke candidate that had been in development with AstraZeneca.

You may also be interested in...



Evotec Acquires Renovis In $152 Million Deal

Agreement will create company with six preclinical and clinical candidates for a broad range of central nervous system applications.

Evotec Acquires Renovis In $152 Million Deal

Agreement will create company with six preclinical and clinical candidates for a broad range of central nervous system applications.

Renovis Gains Funding From Pfizer To Further VR1 Receptor Research

Extension of existing collaboration with Pfizer will fund Renovis’ research in the area through June 30, 2008.

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel